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Abstract
Background: Burkholderia pseudomallei, a Gram-negative bacterium that causes melioidosis, was reported to produce
biofilm. As the disease causes high relapse rate when compared to other bacterial infections, it therefore might be due to
the reactivation of the biofilm forming bacteria which also provided resistance to antimicrobial agents. However, the
mechanism on how biofilm can provide tolerance to antimicrobials is still unclear.
Methodology/Principal Findings: The change in resistance of B. pseudomallei to doxycycline, ceftazidime, imipenem, and
trimethoprim/sulfamethoxazole during biofilm formation were measured as minimum biofilm elimination concentration
(MBEC) in 50 soil and clinical isolates and also in capsule, flagellin, LPS and biofilm mutants. Almost all planktonic isolates
were susceptible to all agents studied. In contrast, when they were grown in the condition that induced biofilm formation,
they were markedly resistant to all antimicrobial agents even though the amount of biofilm production was not the same.
The capsule and O-side chains of LPS mutants had no effect on biofilm formation whereas the flagellin-defective mutant
markedly reduced in biofilm production. No alteration of LPS profiles was observed when susceptible form was changed to
resistance. The higher amount of N-acyl homoserine lactones (AHLs) was detected in the high biofilm-producing isolates.
Interestingly, the biofilm mutant which produced a very low amount of biofilm and was sensitive to antimicrobial agents
significantly resisted those agents when grown in biofilm inducing condition.
Conclusions/Significance: The possible drug resistance mechanism of biofilm mutants and other isolates is not by having
biofilm but rather from some factors that up-regulated when biofilm formation genes were stimulated. The understanding
of genes related to this situation may lead us to prevent B. pseudomallei biofilms leading to the relapse of melioidosis.
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Introduction
Melioidosis is the disease caused by gram negative bacterium,
Burkholderia pseudomallei. The disease is endemic in Southeast Asia
and Northern Australia. Clinical manifestations can be varied
from acute infection, chronic localized pathologic symptoms to
latent infection that may reactivate decades later. In Thailand, the
disease accounts for 20% of all community-acquired septicemias
and the most common cause of the high mortality is septic shock
[1,2]. B. pseudomallei is intrinsically resistant to many antimicrobial
agents including first and second generations of cephalosporins,
penicillins, macrolides, colistin, rifamycins, and aminoglycosides
[3,4]. Ceftazidime (CTZ), the carbapenems such as imipenem
and meropenem, and to a lesser degree amoxicillin-clavulanate,
remain the backbone of current initial or intensive phase
melioidosis treatment. Resistance to CTZ and imipenem (IMN)
is rare. The current standard treatment with agents to which B.
pseudomallei is susceptible requires 2–4 weeks of parenteral therapy
e.g. with CTZ as initial intensive therapy, followed by 3–6 months
of oral eradication therapy e.g. with trimethoprim/sulfamethox-
azole (TMP/SMX), doxycycline (DOX), chloramphenicol or a
combination therapy. Although, CTZ is the drug of choice that is
the most effective for treatment of severe melioidosis, the mortality
rate in treated patients has been found to be more than 40% [2].
B. pseudomallei was reported to form biofilms and microcolonies [5].
The capacity of B. pseudomallei to produce biofilm varied in
quantity in each isolate and there was no correlation between
biofilm production and source of isolation, including the virulence
of bacteria [6]. It was found that biofilm bacteria can be up to
1,000 times more resistant to antimicrobial agents than their free-
living (planktonic) counterpart [7]. Moreover B. pseudomallei was
reported to cause very high relapse rate compared to other
PLoS ONE | www.plosone.org 1 February 2010 | Volume 5 | Issue 2 | e9196bacterial infection [8]. The relapse might be due to reactivation of
the biofilm forming bacteria that made them resist to antimicro-
bials. The role of biofilm in the susceptibility to antimicrobials in
the same planktonic and biofilm strain of B. pseudomallei was never
been reported. Therefore the study of the role of biofilm in
antimicrobial resistance in B. pseudomallei is needed.
Lipopolysaccharide (LPS) of B. pseudomallei seems to differ in
several aspects from the LPS of other gram-negative bacteria and
was found to be largely conserved across this species [9]. LPS
profiling of 1,327 B. pseudomallei isolates are mostly (97%) smooth
type A LPS that possess different ladder profiles from the two less
frequent types, smooth type B and rough type. Interestingly, the
latter were found more in clinical than environmental isolates and
also were more often associated with relapse than with primary
infection [10]. Among these 3 types, type A produced the lowest
amount of biofilm [10]. Apart from being immunogenic and
virulence factors, LPS also acts as a permeability barrier at
bacterial surfaces, particularly to hydrophobic agents [11]. The
modification of LPS upon exposure to some antimicrobial agents
and the defect in LPS structure from mutations have been
reported to cause the loss of its resistance [12]. In B. pseudomallei,
the direct relationship between the differentiation of LPS
phenotypes and the susceptibility to antimicrobial agents,
including the alterations of LPS after the formation of biofilms
or exposure to antimicrobial agents are still unknown.
Quorum sensing (QS) is also one of the putative virulence
factors in B. pseudomallei [13]. In gram-negative bacteria, it is a cell-
density-dependent communication system that uses N-acyl homo-
serine lactones (AHLs) for the coordination of gene expression.
Bacterial biofilms are believed to be an optimum site for the
activation of QS, because it is here that natural populations are at
their highest cell densities. Many studies in other biofilm-forming
bacteria found that biofilm formation and other secreted virulence
factors are QS-required. Therefore, the direct relationship
between QS and biofilm formation in B. pseudomallei also needs
further elucidation.
This is the first study demonstrated that when B. pseudomallei
were grown in condition that induced biofilm formation, they
resisted to all antimicrobial agents tested. We quantified the
biofilm-forming capacity of 50 soil and clinical B. pseudomallei
isolates and 5 mutants with their wild types using a microtiter plate
assay. Based on the Clinical and Laboratory Standards Institute
(CLSI; formerly The National Committee for Clinical Laboratory
Standards (NCCLS) and Calgary Biofilm Device (CBD) assay, the
in vitro susceptibility of planktonic and biofilm cells in each isolate
to DOX, CTZ, IMN, and TMP/SMX were compared by
evaluating the minimum inhibitory concentration (MIC) of
planktonic cells, the MIC of shedding planktonic cells (P-MIC),
and the minimal biofilm elimination concentration (MBEC)
values. Their LPS phenotypes and LPS pattern profiles were
analyzed using SDS-PAGE with silver staining and lastly, the total
AHLs in culture supernatants during planktonic and biofilm-
formed status were quantified using the bioluminescence assay.
Materials and Methods
Bacterial Isolates
Fifty isolates of B. pseudomallei isolated from clinical sources
and soils collected from the northeastern endemic region of the
country during 1987 to 2001 were used in this study (Table 1).
Isolates no. 316a, 316c, 356a, 356c and 979b were kindly
provided by Mrs. Vanaporn Wuthiekanun, Mahidol-Oxford
Research Unit, Faculty of Tropical Medicine, Mahidol University,
Bangkok, Thailand. Capsule, LPS and flagellin defective mutants
Table 1. Detail of 50 B. pseudomallei isolates.
Isolates Source
316a Blood
316c Blood
365a Blood
365c Blood
979b Blood
844 Blood
1-20 Blood
1-1217 Blood
1-184 Blood
A2 Blood
A1 Blood
A15 Blood
H1038 Blood
H602 Blood
H63 Blood
H777 Blood
26-2633av Blood
G12 Pus
3-342 Pus
3-54 Pus
3-82 Pus
3-139 Pus
P87 Pus
P91 Pus
U882b Pus
G207 Sputum
SP278 Sputum
5-19 Sputum
5-307 Sputum
SP340 Sputum
2-173 Urine
U2704 Urine
U2710 Urine
A20 Skin
A16 Skin
A8 Brain
FL202 Fluid
267 Soil from Northeast region of Thailand
279 Soil from Northeast region of Thailand
354 Soil from Northeast region of Thailand
377 Soil from Northeast region of Thailand
409 Soil from Northeast region of Thailand
429 Soil from Northeast region of Thailand
466 Soil from Northeast region of Thailand
591 Soil from Northeast region of Thailand
705 Soil from Northeast region of Thailand
745 Soil from Northeast region of Thailand
847 Soil from Northeast region of Thailand
877 Soil from Northeast region of Thailand
1219 Soil from Northeast region of Thailand
doi:10.1371/journal.pone.0009196.t001
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Woods, Department of Microbiology and Infectious Diseases,
University of Calgary Health Sciences Centre, Canada (Table 2).
Our 2 biofilm mutants (Table 2) were also included in this study
[6]. The mutants were subcultured and grow in Luria-Bertani (LB)
agar containing 15 mg/ml tetracycline.
Biofilm Formation Quantification
A modified microtiter plate test was used to determine the 2-day
biofilm-forming capacities of all isolates as previously described
[6]. The ability of each isolate to produce biofilm was determined
twice in modified Vogel and Bonner’s medium (MVBM) which
was a chemically defined medium used to facilitate the formation
of biofilm [14]. The results reported were the average from two
independent experiments. To compare the relative capacity of
different isolates to produce biofilm, their OD values were
adjusted against that produced by isolate ‘UE5’ of B. thailandensis
which was randomly selected and used as reference in all
experiments. The data was presented as corrected OD630 nm
value when compared with the reference isolate. The capability of
the bacteria to produce biofilm were arbitrarily classified into 3
groups; low biofilm-producing (corrected OD630 nm,1.00), mod-
erate biofilm-producing (corrected OD630 nm=1.00-3.00) and
high biofilm-producing groups (corrected OD630 nm.3.00).
Antimicrobial Susceptibility Testing
MIC assay. The minimal inhibitory concentration (MIC) was
determined and carried out in 96-well microtiter plates and the
interpretation of the results was conducted according to the
criteria established by the CLSI (National Committee for Clinical
Laboratory Standards NCCLS, 2002). Antimicrobial agents were
2-fold serially diluted in Mueller Hinton broth (MHB) with the
final volumes of 50 ml in each well of the plates. For TMP/SMX,
MHB containing thymidine phosphorylase (0.2 units/ml) was
used. A single colony of each bacteria initially grown on a nutrient
agar (NA) plate or LB agar containing 15 mg/ml tetracycline (for
mutants) was inoculated into 10 ml of MHB and incubated at
37uC, 200 rpm for 16 h. The culture was further diluted to
provide a final inoculum density of 0.5-1610
5 CFU/ml in MHB,
which was verified by the total viable count. The final inoculum
(50 ml) was then added in each well of 96-well microtiter plate.
The final concentrations of antimicrobial agents were ranging
from 0.12–256 mg/ml for DOX, 0.5–1024 mg/ml for CTZ,
0.12–256 mg/ml for IMN, and 0.06/1.18-128/2432 mg/ml for
TMP/SMX. Wells containing only media and culture-free
antimicrobial agents were included as negative controls. All
samples were run in duplicate. Plates were then incubated at
37uC for 24 h and the MIC was then read. Quality control of the
activities of antimicrobial agents was conducted using Escherichia
coli ATCC 25922 and the MICs for the control strain were within
NCCLS limits throughout the study.
Antimicrobial preparations for planktonic and biofilm
strains. Serial two fold dilutions of each antimicrobial agent in
MHB were prepared in the 96-well plates for DOX from 0.25–
256 mg/ml, CTZ from 1–1024 mg/ml, IMN from 0.25–256 mg/
ml, and TMP/SMX from 0.12/2.37–128/2432 mg/ml with the
final test volumes of 200 ml in each well. These antimicrobial
plates were used in planktonic and biofilm susceptibility tests.
Planktonic and biofilm susceptibility tests within the
same strains. The Calgary biofilm device (CBD) (MBEC
Biofilms Technology Ltd., Calgary Alberta, Canada) was used
for planktonic and biofilm susceptibility testing as described by
Ceri et al. [15] with slight modifications. The CBD consists of 2
components; the top component forms a lid that has 96 pegs. The
pegs are designed to sit in the channels of the bottom component
of a standard 96-well plate. Each peg will form the equivalent
biofilms [15]. The bacterial biofilm was formed on each pegs in
the culture prepared in fresh MVBM with the initial cell
concentration of 10
7 CFU/mL. A final volume (150 ml) of each
bacterial culture was placed in each well of 96-well microtiter
plate. Medium alone was served as the negative control. The
plates were incubated on the rocking platform (Shaker SK-101,
HL instruments) at 37uC at approximately 100 rpm for 24 h.
Biofilms formed on the lid of the CBD were then transferred to a
standard 96-well plate in which dilutions of the specified antibiotics
were prepared. Antimicrobial agent-free wells were also included for
growth control by adding only the media. Antimicrobial plates were
incubated overnight at 37uCf o r2 4 h ,a f t e rw h i c ht h el i dw a s
removed and the antimicrobial plates were checked for turbidity in
t h ew e l l so nt h em i c r o p l a t er e a d e ra t6 3 0n mf o rd e t e r m i n a t i o no f
P-MIC values. The lid was then rinsed in phosphate-buffered saline,
and placed in a second 96-well plate containing MHB. The biofilm
was removed from the CBD pegs by sonication for 5 min. A new
plate cover was added, and the viability of the biofilmwas determined
after24 h ofincubationat 37uC byreading the turbidity at 630 nm in
a 96-well plate reader for MBEC determinations. The P-MIC is
defined as the minimum concentration of antibiotic that inhibits
growth of the planktonic bacteria shed from the biofilm during the
challenge incubation. The MBEC is defined as the minimum
concentration of antibiotic that inhibits regrowth of biofilm bacteria
in the recovery media. Clear wells (OD630 nm,0 . 1 )a r ee v i d e n c eo f
inhibition.
Characterization of LPS Phenotype
LPS was extracted from individual B. pseudomallei isolates by the
proteinase K digestion method [16]. The LPS phenotype of each
B. pseudomallei isolate was characterized using SDS-PAGE which
was carried out in the discontinuous buffer system in a vertical slab
gel system [17]. The separating gel contained 15% acrylamide and
the stacking gels contained 4% acrylamide. Ten microliters of LPS
sample was loaded into each well and electrophoresed. Electro-
phoresis was carried out at 200 V and LPS bands were then
detected with a modified silver stain [18].
Detection of LPS Alteration in Planktonic and Biofilm
Cells
In order to study the role of LPS pattern profile during
antimicrobial resistance, the B. pseudomallei isolates that had the
antimicrobial tests changed from MIC susceptible to P-MIC and
Table 2. Biofilm-forming capacity of B. pseudomallei mutants
and their wild types.
Isolates
Corrected
OD630 nm
Biofilm-producing
groups
1026b (Wild type) [25] 1.58 Moderate
SR1015 (Capsule-defective mutant) [26] 1.98 Moderate
SRM117 (O-side chain LPS-defective
mutant) [25]
2.00 Moderate
MM35 (Flagellin-defective mutant) [25] 0.37 Low
H777 (Wild type) [6] 3.26 High
M10 (Biofilm-defective mutant) [6] 0.16 Very low
M6 (Biofilm-defective mutant) [6] 0.16 Very low
doi:10.1371/journal.pone.0009196.t002
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316a, U882b, A8) or from MIC and MBEC resistance to P-MIC
susceptible (365a) were selected for LPS profile analysis. The LPS
profile was analyzed by using SDS-PAGE with modified silver
stain as described previously [18] in all isolates that mentioned
above in planktonic, shedding planktonic and biofilm forms. For
planktonic cells, LPS was extracted from overnight broth cultures
in 10 ml of MHB and in 10 ml of MVBM using the method as
described above. For the isolates that gave resistance in P-MIC
values, the planktonic cells that were shed from the pegs were used
for LPS extraction. For the biofilm cells, overnight broth cultures
of 10 mL in MVMB were subcultured into new fresh MVBM
tubes and then incubated statically at 37uC for 2 days. The 2-day
biofilm cultures were then used for LPS extraction.
AHL Assay
AHL production in planktonic and biofilm cells of B. pseudomallei
was assayed as previously described [19]. The culture supernatant
samples were dispensed in aliquots of 100 ml into black 96-well
microtiter plates (MicroBiota 1450-405/511, Wallac, Perkin Elmer,
MA,USA).Each sample wasthen mixedwithanequal volume ofE.
coli indicator cells (JM109 containing pSB401 [Tet
r, luxRluxC-
DABE]) which had been grown to an OD of 1 at 600 nm at 30uCi n
LB broth containing 15 mg/ml tetracycline. The wells containing
only medium were also included as negative controls. The plates
were then incubated at 30uC for 4 h before bioluminescence
counter (Wallac multilabel, PerkinElmer, MA, USA). The amount
of AHL was expressed in counts per second (cps) units.
Statistical Analysis
All data are presented as mean6standard error (SE) and were
analyzed using SPSS version 11.5. Comparisons between two and
more groups were made by using the Mann-Whitney and Kruskal-
Wallis tests. A P value of ,0.05 was considered statistically
significant.
Results
Biofilm Productions in B. pseudomallei Isolates
Thebacterialgrownconditionsinthemicrotiterplatetestof50B.
pseudomallei isolates demonstrated that each isolate produced a
biofilm varying in quantity from one isolate to another (Table 3).
The isolate that produced the minimal biofilm was A2 (corrected
OD630 nm=0.59)whereasthe highestproducingbiofilm was U2704
(corrected OD630 nm=41.91). Most of the soil isolates produced less
biofilm than those from clinical isolates although there was no
significant difference in the amount of biofilm produced between
soil and clinical isolates (means6SE =2.3960.63 and 3.8261.19
respectively).
For the mutants and their wild types, the biofilm-forming
capacity of the capsule-defective mutant, SR1015 and O-side
chain LPS-defective mutant, SRM117, were slightly more than
their 1026b wild type (Table 2). This indicated that the capsule
and O-side chains of LPS do not involve biofilm formation by this
bacterial species. Conversely, the biofilm-forming capacity of the
flagellin-defective mutant, MM35, was markedly reduced when
compared with its wild type. For biofilm defective mutants, both
Table 3. Biofilm-forming capacity of 50 B. pseudomallei isolates.
Low biofilm
producing group
(n=16)
Moderate biofilm
producing group
(n=20)
High biofilm
producing group
(n=14)
Isolates corrected OD630 nm Isolates corrected OD630 nm Isolates corrected OD630 nm
267 0.86 409 1.28 279 3.84
354 0.79 705 1.79 377 7.18
429 0.87 844 1.32 U882b 6.98
466 0.95 877 1.36 745 3.63
591 0.84 1-20 1.09 1219 6.96
847 0.87 2-173 1.42 A15 4.90
3-342 0.98 3-82 1.54 A20 3.46
3-54 0.77 1-184 1.31 A8 5.22
5-19 0.85 5-307 1.73 G207 9.88
1-1217 0.84 A1 1.87 H777 3.26
3-139 0.60 FL202 1.00 SP278 4.09
A2 0.59 G12 2.17 U2704 41.91
H1038 0.89 H602 1.15 U2710 15.03
H63 0.88 P87 1.06 A16 13.06
316c 0.92 P91 1.70
979b 0.63 SP340 2.67
316a 1.58
365a 1.13
365c 1.56
26-2633av 1.15
Mean6SE 0.8260.12 Mean6SE 1.4960.09 Mean6SE 9.2462.69
doi:10.1371/journal.pone.0009196.t003
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expected since they were biofilm-defective mutants.
Susceptibility of Planktonic and Biofilm Cells of
B. pseudomallei to Antimicrobial Agents
The concentrations of four antimicrobial agents required to
inhibit planktonic cells (MIC), shedding planktonic cells (P-MIC)
and those required to kill biofilm bacteria (MBEC) of low,
moderate and high biofilm producing B. pseudomallei isolates are
shown in Figure 1. Most of the MICs and P-MICs of all
antimicrobial agents used gave similar results. From the MIC and
P-MIC results, all isolates were susceptible to IMN (Figure 1C).
Most isolates except A15 were susceptible to DOX (Figure 1A).
A15 was susceptible by MIC but resistant by P-MIC. Five clinical
isolates, 316c, 365a, 979b and A8, A16 were resistant to CTZ
when determined either by MIC and P-MIC respectively
(Figure 1B). The remaining isolates were susceptible while 10
isolates, FL202, 5-19, 1-1217, 316c, 705, 844, 3-82, 316a, U882b
and A8 were resistant to TMP/SMX as determined by P-MIC
values (Figure 1D). When these bacteria were induced to form
biofilm, they were highly resistant (MBEC results) to all
antimicrobial agents tested. Only 2 biofilm bacteria, 979b and
P91, were found to be susceptible to DOX.
Most of the planktonic cells of all 3 biofilm-producing groups,
low, moderate, and high, were susceptible to all antimicrobial
agents tested. When the MIC, P-MIC, and MBEC values among
three biofilm-producing groups were compared, there were no
significant differences in antimicrobial resistance. These data also
indicated that, when bacteria were induced to form biofilms, most
of them exhibited resistance to antimicrobial agents as shown in
the MBEC values regardless of their biofilm-producing capacity.
From the MIC and P-MIC results, the wild type isolates, 1026b
and H777, were susceptible to all antimicrobial agents (Figure 2)
whereas the biofilm cells of these 2 isolates were resistant. All
mutants except MM35 were resistant to DOX and TMP/SMX
(Figure 2A and 2D). None of the mutants were resistant to CTZ
and IMN (Figure 2B and 2C). When all mutants were induced to
form biofilms, they were highly resistant to all antimicrobial agents
even in biofilm-defective mutants, M10 and M6 (Figure 2). Since
all mutants were constructed using transposon containing the Tet
R
gene, they were therefore found to be resistant to DOX
(Figure 2A).
LPS Phenotype of B. pseudomallei during Biofilm
Production and Antimicrobial Resistance
Of 50 B. pseudomallei isolates, 39/50 or 78% possessed smooth
type A and 14% or 7/50 possessed smooth type B LPS. The
remaining 4/50 or 8% without a ladder appearance possessed the
rough type. For mutants, all strains exhibited the LPS phenotype
similar to their wild types with the exception of SRM117 which
possessed the rough type phenotype since it lacked O-side chain
moiety in the LPS structure (data not shown). The smooth type B
and rough type LPS B. pseudomallei isolates appeared to have a
significantly higher capacity to produce biofilm than the smooth
type A (P,0.05). The corrected OD630 nm values (mean6SE)
obtained from smooth type B and rough type LPS B. pseudomallei
were 10.3765.56 and 7.3662.55, while that value of smooth type
A B. pseudomallei was 1.8160.26. No significant difference of
biofilm producing capacity was observed between the smooth type
B and rough type LPS B. pseudomallei isolates.
The LPS patterns in figure 3 demonstrated the examples of 4
from 12 isolates which all of them showed no alteration of LPS
phenotype when the bacteria changed from MIC susceptible to
P-MIC and MBEC resistances (A16, 5-19 and U882b) or MIC
and MBEC resistances to P-MIC susceptible (365a) (Figure 2).
AHL Synthesis in Planktonic and Biofilm Cells of
B. pseudomallei Isolates
The amount of AHL in the culture supernatants of 2-day
biofilm cells in all biofilm-producing groups were significantly
higher than those of planktonic cells (P,0.05) (Figure 4). The
amount of AHL, however, did not correlate with the biofilm
producing capability of B. pseudomallei.
Discussion
Melioidosis is still a serious infectious disease that requires a long
course of antimicrobial therapy such as intravenous CTZ or
carbapenems for at least 10 days, followed by oral antimicrobial
agents, DOX, TMP/SMX or combination therapy for at least 12
weeks [20]. Relapse of the disease is still common despite adequate
antimicrobial therapy [8]. B. pseudomallei was reported to form
biofilm both in laboratory media and in animal model [5]. The
role of biofilms in protecting B. pseudomallei against antimicrobial
agents has been reported in one study using a modified Robbins
device [21]. The biofilm cells in their study were still viable after
24 h of antimicrobial exposure, with up to 200 times of the MIC of
planktonic cells. However, only one B. pseudomallei isolate was
tested against CTZ and TMP-SMX. Moreover, it was not the
direct comparison between the planktonic and biofilm cells of the
same B. pseudomallei isolate. The used of the Calgary Biofilm
Device, MBEC
TM device [15], in our study can directly compare
the antimicrobial resistance of the bacterial sloughed or shed from
the surface of the readily formed biofilm and serve as the inoculum
for P-MIC and MBEC determinations. Although the P-MIC
values obtained using the MBEC
TM device are similar to those
obtained using the NCCLS procedure [15], a difference of
planktonic MIC values between 1 to 3 dilutions when obtained
from both assays was observed. Therefore, in this study the
NCCLS assay for planktonic MIC determination using the
standard microdilution was performed in parallel with the
MBEC
TM assay. In the mutant study, the biofilm-forming capacity
of capsule-defective SR1015 and O-side chain LPS-defective
SRM117 mutants was slightly higher than their 1026b wild type
while the MM35 flagellin-defective mutant produced the lowest
biofilm quantity. This result suggested that flagellin, but not
capsule nor LPS, was required for biofilm formation. The flagellin
may be required for adherence of the planktonic cells to the
surface, since it has been reported that flagella and twitching
motility were necessary in the development of Pseudomonas
aeruginosa biofilms formation [22].
Most of the 50 B. pseudomallei planktonic cells were susceptible to
all antimicrobial agents used in this study. This confirmed previous
reports on the in vitro susceptibility to antimicrobial agents of B.
pseudomallei isolates with the current recommendations of these
drugs for the treatment of melioidosis [23]. The MIC and P-MIC
values were within the susceptible limits but varied in their ranges
compared to the previous report [23]. There were some isolates
that gave different results. This dissimilarity might be due to the
different of methods since MIC is antibiotic efficacy tested against
bacteria from seeding whereas P-MIC is the antibiotic efficacy
tested against the planktonic bacteria shed from the biofilm.
Among antimicrobial agents used, IMN showed the greatest
activity with extremely low MIC values and the planktonic cells of
all isolates were susceptible to this drug. This suggested the use of
IMN as an alternative to CTZ in the treatment of disseminated or
severe melioidosis or in case of resistance to CTZ. In contrast, the
B.pseudomallei Drug Resistance
PLoS ONE | www.plosone.org 5 February 2010 | Volume 5 | Issue 2 | e9196Figure 1. The response of B. pseudomallei planktonic and biofilm cells to antimicrobial agents. Susceptibility of planktonic and biofilm
cells of B. pseudomallei isolates to doxycycline (DOX; A), ceftazidime (CTZ; B), imipenem (IMN; C) and trimethoprim/sulfamethoxazole (TMP/SMX; D)
were shown. The cut off (---) indicates the resistant lines.
doi:10.1371/journal.pone.0009196.g001
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PLoS ONE | www.plosone.org 6 February 2010 | Volume 5 | Issue 2 | e9196Figure 2. The response of B. pseudomallei mutants and their wild type to antimicrobial agents. Susceptibility of B. pseudomallei mutants
and their wild types to doxycycline (DOX; A), ceftazidime (CTZ; B), imipenem (IMN; C), and trimethoprim/sulfamethoxazole (TMP/SMX; D) were shown.
The cut off (---) indicates resistant lines. The astericks (*) refer to resistant strains.
doi:10.1371/journal.pone.0009196.g002
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SMX, and 3 isolates (6%, 3/50), 316c, 365a and 979b, were
resistant to CTZ (Figure 1). The primary CTZ resistance in these 3
isolates has been proved to result from their own b-lactamase-
based mechanisms for CTZ [24]. The resistance to DOX of all
planktonic mutants was due to transposon-carrying tetracycline-
resistant genes that be inserted into the wild type strain in the
mutant construction process [25,26]. It was also observed that
these planktonic mutants were likewise resistant to TMP/SMX,
except for the flagellin-defective mutant, MM35. The underlying
mechanism of this finding is still unknown and may possibly be
due to the random insertion of tranposons and affects the
expression of resistance genes for this antimicrobial agent.
The biofilm cells B. pseudomallei were shown to be markedly more
resistant to antimicrobial agents than the corresponding planktonic
cells within the same isolate, consistent with the results obtained
using the same methods in other biofilm bacteria [27]. Several
mechanisms were proposed in the role of how the biofilm affects
antimicrobial resistance including the antibiotic diffusion limitations
of the biofilm matrix and the heterogeneity of growth rates within
the biofilm [28]. The difference of bacterial density throughout the
biofilm determines gradients of nutrients and oxygen availability
within biofilm structure, results in differences of metabolic activity
among bacteria that could restrict the growth of bacteria [29].
Because most antimicrobial agents primarily target metabolically
active cells, the slow growth rate and metabolic heterogeneity in
biofilm cells have been proposed to contribute resistance to
antimicrobial agents, particularly the b-lactams [30,31]. Our result
demonstrated that high resistance still occurred even in our two
biofilm-defective mutants. The mechanism of biofilm as barrier in
antimicrobial diffusion is therefore unlikely. The resistant mecha-
nism might not be due to the biofilm formation by itself but because
of the conditions that induced the biofilm formation. Because the
biofilm formation is multifactorial process, when the biofilm gene
operon was induced, it might also induce some other set of genes or
some other mechanisms which responsible for drug resistance. No
correlation between amount of biofilm and AHL productions in our
50 B. pseudomallei isolates and antimicrobial resistance were another
evidence to support our hypothesis. Moreover, biofilm formation
was reported to enhance the rate of mutability due to the
accumulation of DNA damage [32]. This may enhance the
opportunity to drive the selection of antibiotic-resistant organisms
[32]. CTZ and IMN, the two b-lactams antibiotics, were totally
ineffective in killing B. pseudomallei biofilm cells. The explanation of
this resistance may be due to slow growth rate. The studies done in
P. aeruginosa demonstrated that b-lactams and tetracycline showed
Figure 3. LPS profiles of planktonic, shedding planktonic and biofilm cells of B. pseudomallei isolates during changing their
antimicrobial susceptibility. LPS profiles of rough type isolate, A16 (Panel A) and smooth type A LPS isolate, 5-19, (Panel B), during planktonic
status cultured in MHB medium in lane 1, MVBM medium in lane 2, shedding planktonic status in lane 3, and 2-day biofilm-formed status in lane 4.
The LPS profile of smooth type B isolate, U882b (Panel C) obtained from its planktonic status in MVBM medium (lane 1), shedding planktonic (lane 2),
and 2-day biofilm-formed status (lane 3). (Panel D) LPS profile of 365a isolate which was resistant to CTZ during planktonic status cultured in MHB
medium (lane 1) and MVBM medium (lane 2), and 2-day biofilm-formed status (lane 3).
doi:10.1371/journal.pone.0009196.g003
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aeruginosa biofilm producers [33,34]. Alternatively, CTZ could be
destroyed by the production of inactivating enzymes such as b-
lactamase that accumulated within the glycocalyx of the P. aeruginosa
biofilm [35,36]. The resistance mechanism to TMP/SMX in B.
pseudomallei biofilm organisms is still unclear, although it has been
documented as being due to the production of a different
dihydrofolate reductase enzyme in planktonic-resistant cells [37].
LPS has been shown to be important for the resistance of the
bacteria to antimicrobial agents due to its barrier to antimicrobial
penetration [38]. The nature of this barrier is associated with
changes in the composition and phenotype of LPS in different
bacterial species tested [39,40,41]. For B. pseudomallei, the results
showed that the LPS extracted from the planktonic, biofilm and
shedding cell of the same organisms gave the same LPS pattern
profiles. Moreover, the difference in LPS phenotypes was not
correlated with MIC, P-MIC, or MBEC. This indicated that the
composition or phenotype of LPS was not altered while forming
biofilms and was not correlated with the antimicrobial resistance
mechanism in B. pseudomallei.
Within the genus Burkholderia, particularly in some strains of
B. cenocepacia and B. cepacia, their quorum sensing (QS) systems
positively regulated expression of swarming motility and biofilm
formation [42]. These QS were not involved in the regulation of
initial cell attachment but rather controlled the maturation of the
biofilm. From our results, a significant difference in the AHLs was
detected in culture supernatants of planktonic when compared with
biofilm-formed cells. This indirectly suggests that these isolates
utilized AHLs to regulate the high biofilm production. Nevertheless,
the highly resistant biofilm cells were not AHL dependent since
there were no differences in MBEC values in the different of AHLs
production(datanotshown).Thisfindingissimilartowhathasbeen
observed in B. cenocepacia biofilms [43]. Moreover, the production of
AHLs was not correlated with the phenotypes of LPS and the
biofilm-forming capacity. It should be kept in mind that the biofilm
AHLs detected in culture supernatants are not the total amounts.
These levels of AHLs could not be extrapolated to the presence of
AHLs within the biofilms themselves. Although it has been
demonstrated that B. pseudomallei could produce numerous AHLs
[13,44,45], the one that play a direct role in biofilm production is
still unknown. The clinical importance of AHL-mediated biofilm
formation and the directly regulated-QS circuits involved in B.
pseudomalli are the subject of an on-going investigation.
In conclusion, the conditions to induce B. pseudomallei biofilm
formation were proven to be highly resistant to all antimicrobial
agents tested when compared to the corresponding planktonic cells
of the same isolates. The barrier of biofilm in preventing the drug
penetration was proved to be unlikely and the biofilm mutant which
resistant to all drugs after they were induced to form biofilm raised a
possible mechanism of drug resistance that may be up-regulated
together with the stimulationofbiofilmformation. The biofilm cells,
if present in vivo during bacterial infection might contribute to a long
persistence of the bacteria and consequence to the high relapse of
the disease. The contribution of AHL in their higher biofilm
production was proposed but LPS phenotypes did not change
during the antimicrobial resistance or biofilm production. The
understanding of this phenomenon will lead insights in the control
of biofilm formations and prevention of relapse in melioidosis.
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